Loading...
Market
Market share of ACAM2000 in mpox vaccine market by end of 2024?
2
Resolution / Starting Odds
Less than 25% • 25%
25-50% • 25%
50-75% • 25%
More than 75% • 25%
Market research reports and industry analysis
Story
FDA Approves Emergent's ACAM2000 Mpox Vaccine, Stock Soars 23%
Aug 30, 2024, 05:50 AM
The U.S. Food and Drug Administration (FDA) has approved the expanded use of Emergent BioSolutions' ACAM2000®, a live smallpox vaccine, to include individuals at high risk for mpox infection. This approval comes amid ongoing mpox outbreaks across Africa and other regions, highlighting a critical public health challenge. Following the FDA's decision, Emergent BioSolutions' stock saw a significant increase, soaring by 23%. The ACAM2000 vaccine, initially developed for smallpox, will now play a crucial role in addressing the public health challenge posed by mpox.
View original story
Similar markets
Less than 30% • 25%
30% to 50% • 25%
50% to 70% • 25%
More than 70% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20-40% • 25%
41-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Capvaxive leads • 33%
Prevnar 20 leads • 33%
Equal market share • 33%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Pfizer • 25%
GlaxoSmithKline • 25%
Moderna • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%